“eteplirsen” Archives

in
Entry Author Date Location
With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor 08/12/20 New York
Court Rules More Trial Data Must Be Posted On ClinicalTrials.gov 03/04/20 National
FDA Flags Risk of Infection, Kidney Damage for Sarepta Duchenne Drugs 01/22/20 Boston
Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More 12/13/19 National
In an About-Face, FDA Approves Second Sarepta Muscular Dystrophy Drug 12/13/19 Boston
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More 08/23/19 National
FDA Rejects Sarepta’s Second Duchenne Drug, Citing Safety Concerns 08/19/19 Boston
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More 08/02/19 National
Duchenne Advocates Start Casimir, Aiming to Capture Missing Data 07/26/19 Boston
With Its First Human Data, Solid Slips in Duchenne Gene Therapy Race 02/07/19 Boston
Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More 12/21/18 National
15 for ’19: Key Clinical Data to Watch for Next Year (Part 1) 12/17/18 National
Sarepta Touts New Data and a “Signal” With Duchenne Gene Therapy 10/03/18 Boston
Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure 06/27/18 Boston
Sarepta’s Data Are First in Rush for Duchenne Gene Therapy 06/19/18 Boston
Bio Roundup: IDO Fallout, Express Scripts Dumps Amgen, Isaly Out & More 05/04/18 National
Life Sci Veteran Garabedian Talks Up Biotech Accelerator in Texas 04/23/18 Texas
Solid Discloses Duchenne Problems in IPO & Raises Rival’s Hackles 01/25/18 Boston
Bio Roundup: Migraine Data, Cancer Drug Combos, Azar Hearing & More 12/01/17 National
Ed Kaye on Sarepta’s Duchenne Quest, Rising to CEO & His New Startup 11/20/17 Boston
With $40M for Exonics, Duchenne’s Gene Therapy, CRISPR Race Heats Up 11/08/17 Boston
FDA Panel Pans PTC’s Audacious Plan to Force Vote on Duchenne Drug 09/28/17 New York
Bio Roundup: GOP Drama, Immunotherapy Setbacks, Pharma Revamps 07/28/17 National
Woodcock: New Approvals Show FDA Is Adapting to Precision Medicine 05/30/17 National
Ex-Sarepta CEO Garabedian Returns to Run Bio Accelerator Xontogeny 05/18/17 Boston
Analysts Expect Payer Pushback as PTC Sets $35K Price For Duchenne Drug 05/08/17 New York
After Sarepta’s Surprising FDA Nod, CEO Kaye Plans to Resign 04/28/17 Boston
Duchenne, SMA, and the Rise of Patient Power at “What’s Hot” on May 11 04/27/17 Boston
Next Stop on Father’s Duchenne Quest: Wall Street? Solid Raises $50M 03/30/17 Boston
After a Clinical Trial Death, FDA OKs New Tests of Akashi’s Duchenne Drug 03/22/17 Boston
Page 1 of 3 next page »